title: The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
abstract: Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In May 2015, the FDA issued a warning of ketoacidosis with use of this drug class. Risk factors for the development of ketoacidosis among patients who take SGLT-2 inhibitors include decrease carbohydrate intake/starvation, acute illness and decrease in insulin dose. When identified, immediate cessation of the medication and administration of glucose must be done, and in some instances, starting an insulin drip might be necessary. We present a case of a patient with diabetes mellitus being on empagliflozin (SGLT-2 antagonist) who was admitted for acute cholecystitis. The hospital course was complicated by euglycemic diabetic ketoacidosis after being kept nothing per orem before a contemplated cholecystectomy.
authors.affiliation: Department of Internal Medicine, Einstein Healthcare Network, Philadelphia , USA.
authors.forename: Nellowe
authors.initials: N
authors.lastname: Candelario
authors.affiliation: Department of Internal Medicine, Einstein Healthcare Network, Philadelphia , USA.
authors.forename: Jedrzej
authors.initials: J
authors.lastname: Wykretowicz